30 Mg Octreotide Long Acting Release Injection

Name: 30 Mg Octreotide Long Acting Release Injection
Brand: NEETCO BIOPHARMA
Price: 15500 INR
Availability: InStock

Price 15500 INR/ Piece

Get a Price/Quote

MOQ : 1 Piece

30 Mg Octreotide Long Acting Release Injection Specification

Origin of Medicine
Allopathic

Salt Composition
Octreotide Acetate

Indication
Treatment of acromegaly, carcinoid tumors, and vasoactive intestinal peptide tumors (VIPomas)

Dosage Form
Long Acting Injection (LAR)

Pacakaging (Quantity Per Box)
1 vial + 1 ampoule solvent + injection accessories

Drug Type
Prescription only

Ingredients
Octreotide Acetate 30 mg

Physical Form
Injection

Function
Antineoplastic and hormonal agent, suppresses growth hormone and certain peptide hormones

Recommended For
Adults (consult physician for pediatric usage)

Dosage
As directed by physician, typically 30 mg via intramuscular injection once every 4 weeks

Dosage Guidelines
Administered only by healthcare professionals via deep intramuscular injection

Suitable For
Adults

Quantity
1 vial per pack

Storage Instructions
Store at 2°C - 8°C. Do not freeze. Protect from light.

Shelf Life
24 months from date of manufacture

Contraindication
Hypersensitivity to Octreotide or excipients

Brand Name
Octreotide LAR 30 mg

Usage
For long-term management of neuroendocrine tumors and hormonal disorders

Formulation
Lyophilized powder with accompanying solvent

Color
White to off-white lyophilized powder

Box Contents
1 vial (30 mg), 1 ampoule solvent (diluent), syringe, and instructions leaflet

Route of Administration
Intramuscular (gluteal muscle)

Manufactured By
Reputed pharmaceutical manufacturer (see outer pack for specific name)

Caution
To be used under medical supervision only

Side Effects
Injection site pain, gallstones, abdominal pain, diarrhea

About 30 Mg Octreotide Long Acting Release Injection

Octreotide LAR 30 mg is a crowning champion in the realm of advanced hormonal therapy, offering valiant support for adults battling neuroendocrine tumors and acromegaly. This best-seller boasts customizable treatment options, presenting a lowest price advantage without compromising on trusted efficacy. Formulated as a white to off-white lyophilized powder-paired with an ampoule of solvent and injection kit-each box is meticulously crafted by reputed pharmaceutical experts. Administered intramuscularly, this prescription-only antineoplastic agent offers long-acting, targeted hormone suppression, delivering reliable results over a 24-month shelf life. Use only under medical supervision.

Exceptional Features and Clinical Uses

Octreotide LAR 30 mg is tailored for the long-term management of conditions such as acromegaly, carcinoid tumors, and VIPomas. Its robust lyophilized formulation ensures stability and ease of reconstitution, while the included injection accessories streamline administration. Intended for deep intramuscular injection by healthcare professionals, this injection provides consistent hormone suppression over four weeks, making it indispensable in the treatment of chronic endocrine disorders.

Sample Availability, Recognized Quality, and Secure Packaging

Samples of Octreotide LAR 30 mg are available to verified healthcare distributors and institutions upon request. Certified by relevant health authorities, each shipment is securely packed-1 vial, 1 ampoule of solvent, syringe, and leaflet-in tamper-evident packaging to ensure product integrity during transport. Our reliable freight and transport services guarantee timely, temperature-controlled delivery, safeguarding efficacy from manufacturer to destination.

FAQ's of 30 Mg Octreotide Long Acting Release Injection:

Q: How is Octreotide LAR 30 mg administered?

A: This medication is given as a deep intramuscular injection, typically by a healthcare professional, into the gluteal muscle every four weeks as directed by a physician.

Q: What conditions does Octreotide LAR 30 mg treat?

A: Octreotide LAR 30 mg is used for the long-term treatment of acromegaly, carcinoid tumors, and vasoactive intestinal peptide tumors (VIPomas) in adults.

Q: When should this injection be avoided?

A: Octreotide LAR 30 mg should not be used by individuals with known hypersensitivity to Octreotide or any component of the formulation.

Q: What benefits does this injectable formulation offer?

A: The long-acting release formulation ensures steady control of hormone levels, reducing the frequency of dosing and supporting improved patient compliance in chronic conditions.

Q: Where should Octreotide LAR 30 mg be stored?

A: The product should be refrigerated at 2C - 8C, not frozen, and protected from light to maintain stability throughout its shelf life.

Q: What are the possible side effects of this medication?

A: Common side effects include injection site pain, abdominal discomfort, diarrhea, and possible gallstone formation. Always consult your doctor about any side effects experienced.

Tell us about your requirement